Larynx Preservation Clinical Trial Design: Summary of Key Recommendations of a Consensus Panel
Author:
- 1 October 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (S3) , 25-29
Abstract
An international consensus panel was convened to develop guidelines for the conduct of phase III clinical trials of larynx preservation in patients with locally advanced laryngeal and hypopharyngeal cancer. According to their recommendations, future trial populations should include patients with T2 or T3 laryngeal or hypopharyngeal squamous cell carcinoma not considered for partial laryngectomy and should exclude those with laryngeal dysfunction or aged >70 years. Baseline and post-treatment functional assessments should include speech and swallowing evaluations. Furthermore, voice should be routinely assessed with a simple, validated instrument. Regarding endpoints, the primary endpoint should capture survival and function. As a result, the panel created a new endpoint of laryngoesophageal dysfunction (LED)-free survival, which includes the events of death, local relapse, total or partial laryngectomy, tracheotomy at ≥2 years, or feeding tube at ≥2 years. Recommended secondary endpoints are freedom from LED, overall survival, progression-free survival, locoregional control, time to tracheotomy, time to laryngectomy, time to discontinuation of feeding tube, and quality of life/patient-reported outcomes. Future exploratory correlative biomarker studies should include epidermal growth factor receptor, excision repair cross-complementation group 1 gene, E-cadherin and β-catenin, epiregulin and amphiregulin, and TP53 mutation. Revised trial designs in several key areas are needed to advance the study of larynx preservation. With consistent methodologies, clinical trials can more effectively evaluate and quantify the therapeutic benefit of novel treatment options for patients with locally advanced laryngeal and hypopharyngeal cancer.Keywords
Funding Information
- Cancer Communications and Consultancy Ltd.
This publication has 24 references indexed in Scilit:
- 8501 Larynx preservation using induction chemotherapy followed by radiation – five-year evaluation of swallowing and laryngeal functions for patients enrolled in the GORTEC 2000–01 randomized studyEuropean Journal of Cancer Supplements, 2009
- Larynx preservation clinical trial design: Key issues and recommendations—A consensus panel summaryHead & Neck, 2009
- Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and RadiotherapyJNCI: Journal of the National Cancer Institute, 2009
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR TargetingClinical Cancer Research, 2006
- Development and Validation of the Voice Handicap Index‐10The Laryngoscope, 2004
- Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal CancerNew England Journal of Medicine, 2003
- Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III TrialJNCI: Journal of the National Cancer Institute, 1996
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerNew England Journal of Medicine, 1991